Concurrent Investment Advisors’s Royalty Pharma RPRX Stock Holding History

Concurrent Investment Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$4.34M	Buy	+74,307	New	+$4.38M	0.03%	523

Other funds holding RPRX

Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return

Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Triasima Portfolio Management Montreal, Quebec, Canada $758M AUM 48.16% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

ASR Vermogensbeheer Utrecht, Netherlands $10.1B AUM 30.4% 1-Year Est. Return

IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

Kearns & Associates Palos Verdes Estates, California $218M AUM 16.36% 1-Year Est. Return

Concurrent Investment Advisors's RPRX Position: Q3 2026 in Review

Concurrent Investment Advisors opened a new position in Royalty Pharma (RPRX) in Q3 2026: 74,307 shares worth $4.34M. The stake represents 0.03% of the portfolio and ranks #523 among its holdings.

67 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

Concurrent Investment Advisors held 74,307 shares of Royalty Pharma worth $4.34M as of Q3 2026.
Royalty Pharma was a new Concurrent Investment Advisors position in Q3 2026.
Royalty Pharma made up 0.03% of Concurrent Investment Advisors's portfolio in Q3 2026, its #523 holding.
67 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on Concurrent Investment Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.